
Chronic intermittent hypoxia induces cardiac inflammation and dysfunction in a rat obstructive sleep apnea model
Qin Wei, Yeping Bian, Fuchao Yu, Qiang Zhang, Guanghao Zhang, Yang Li, Songsong Song, Xiaomei Ren, Jiayi Tong
Journal of Biomedical Research ›› 2016, Vol. 30 ›› Issue (6) : 490-495.
Chronic intermittent hypoxia induces cardiac inflammation and dysfunction in a rat obstructive sleep apnea model
Chronic intermittent hypoxia is considered to play an important role in cardiovascular pathogenesis during the development of obstructive sleep apnea (OSA). We used a well-described OSA rat model induced with simultaneous intermittent hypoxia. Male Sprague Dawley rats were individually placed into plexiglass chambers with air pressure and components were electronically controlled. The rats were exposed to intermittent hypoxia 8 hours daily for 5 weeks. The changes of cardiac structure and function were examined by ultrasound. The cardiac pathology, apoptosis, and fibrosis were analyzed by H&E staining, TUNNEL assay, and picosirius staining, respectively. The expression of inflammation and fibrosis marker genes was analyzed by quantitative real-time PCR and Western blot. Chronic intermittent hypoxia/low pressure resulted in significant increase of left ventricular internal diameters (LVIDs), end-systolic volume (ESV), end-diastolic volume (EDV), and blood lactate level and marked reduction in ejection fraction and fractional shortening. Chronic intermittent hypoxia increased TUNNEL-positive myocytes, disrupted normal arrangement of cardiac fibers, and increased Sirius stained collagen fibers. The expression levels of hypoxia induced factor (HIF)-1α, NF-kB, IL-6, and matrix metallopeptidase 2 (MMP-2) were significantly increased in the heart of rats exposed to chronic intermittent hypoxia. In conclusion, the left ventricular function was adversely affected by chronic intermittent hypoxia, which is associated with increased expression of HIF-1α and NF-kB signaling molecules and development of cardiac inflammation, apoptosis and fibrosis.
obstructive sleep apnea / model chronic intermittent hypoxia / cardiac dysfunction / inflammation
Tab.1 Echocardiographic parameters of the control and CIH rats |
Parameter | Control | CIH | P |
---|---|---|---|
IVSd (mm) | 1.495±0.422 | 1.425±0.386 | 0.1037 |
IVSs (mm) | 2.137±0.562 | 2.151±0.498 | 0.7951 |
LVIDd (mm) | 6.261±1.875 | 6.582±2.015 | 0.0876 |
LVIDs (mm) | 3.060±0.923 | 4.094±1.131 | 0.0002 |
LVPWd (mm) | 1.565±0.181 | 1.686±0.365 | 0.0319 |
LVPWs (mm) | 2.559±0.423 | 2.759±0.598 | 0.0301 |
EDV (cm3) | 0.562±0.109 | 0.652±0.102 | 0.0029 |
ESV (cm3) | 0.070±0.024 | 0.171±0.054 | <0.0001 |
EF (%) | 87.290±9.436 | 74.247±10.345 | 0.0022 |
SV (cm3) | 0.492±0.112 | 0.482±0.010 | 0.4190 |
FS (%) | 51.170±12.425 | 38.127±11.564 | 0.0002 |
CIH: chronic intermittent hypoxia; IVSd: the intervernicular septum in diastole; IVSs: the intervernicular septum in systole; LVIDd: left ventricular internal diameter in diastole; LVIDs: left ventricular internal diameter in systole; LVPWd: the left ventricle posterior wall in diastole; LVPWs: the left ventricle posterior wall in systole; EDV: the volume of blood within a ventricle immediately before a contraction is known as the end-diastolic volume; ESV: the volume of blood left in a ventricle at the end of contraction is end-systolic volume; EF: ejection fraction is the fraction of blood in the left and center ventricles pumped out with each heartbeat; SV= EDV-ESV; FS: fractional shortening. |
Fig.2 CIH caused cellular death and structural changes in rat hearts.A: H&E staining showed increased cardiomyocyte size, disrupted cardiac structure (arrow head) in CIH rat hearts. B: Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay detected significantly increased apoptotic myocytes (arrows) in CIH rats. C: CIH rats had significant fibrosis in Sirius-stained slices. |
[1] |
Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea[J]. Lancet, 2014, 383(9918): 736–747
Pubmed
|
[2] |
Sforza E, Chouchou F, Collet P,
Pubmed
|
[3] |
Peppard PE, Young T, Barnet JH,
Pubmed
|
[4] |
Sharma SK, Ahluwalia G. Epidemiology of adult obstructive sleep apnoea syndrome in India[J]. Indian J Med Res, 2010, 131: 171–175
Pubmed
|
[5] |
Ip MS, Lam B, Lauder IJ,
Pubmed
|
[6] |
Vrints H, Shivalkar B, Hilde H,
Pubmed
|
[7] |
Chirinos JA, Gurubhagavatula I, Teff K,
Pubmed
|
[8] |
Loredo JS, Clausen JL, Nelesen RA,
Pubmed
|
[9] |
Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease[J]. J Am CollCardiol, 2003, 41(9): 1429–1437
Pubmed
|
[10] |
Chen L, Einbinder E, Zhang Q,
Pubmed
|
[11] |
Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications[J]. J Am CollCardiol, 2011, 57(2): 119–127
Pubmed
|
[12] |
Kasai T. Sleep apnea and heart failure[J]. J Cardiol, 2012, 60(2): 78–85
Pubmed
|
[13] |
Baguet JP, Barone-Rochette G, Tamisier R,
Pubmed
|
[14] |
Gao YH, Chen L, Ma YL,
|
[15] |
Lee SD, Kuo WW, Lin JA,
Pubmed
|
[16] |
Badran M, Ayas N, Laher I.Cardiovascular Complications of Sleep Apnea: Role of Oxidative Stress[J]. Oxid Med Cell Longev, 2014, 2014:985258.
|
[17] |
Javaheri S, Javaheri S, Javaheri A. Sleep apnea, heart failure, and pulmonary hypertension[J]. Curr Heart Fail Rep, 2013, 10(4): 315–320
Pubmed
|
[18] |
Li S, Feng J, Wei S,
Pubmed
|
[19] |
Kumar S, Seqqat R, Chigurupati S,
Pubmed
|
/
〈 |
|
〉 |